ErlindaMariaGordonMD
Pediatric Hematology & Oncology • Santa Monica, CAAssociate Professor, Pediatrics, USC School of Medicine
Are you Dr. Gordon?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 33 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
2811 Wilshire Blvd
Suite # 414
Santa Monica, CA 90403Phone+1 323-669-2121Fax+1 323-660-7128
Summary
- Dr. Erlinda Gordon, MD is a pediatric hematologist/oncologist in Santa Monica, California. She is currently licensed to practice medicine in California and Ohio. She is an Associate Professor at USC School of Medicine.
Education & Training
Case Western Reserve Univ/Univ Hosps Cleveland Med Ctr/Rainbow Babies and Childrens HospitalFellowship, Pediatric Hematology/Oncology, 1976 - 1978
The MetroHealth System/Case Western Reserve UniversityResidency, Pediatrics, 1974 - 1976- The MetroHealth System/Case Western Reserve UniversityResidency, Pathology-Anatomic and Clinical, 1973 - 1974
St Alexis HospitalInternship, Transitional Year, 1972 - 1973
University of Santo TomasClass of 1971
Certifications & Licensure
CA State Medical License 1990 - 2026
OH State Medical License 1979 - 1996
Clinical Trials
- SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma Start of enrollment: 2017 Apr 13
- Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers Start of enrollment: 2017 Aug 24
- BLESSED: Expanded Access for DeltaRex-G for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast
Publications & Presentations
PubMed
- Proceedings of the Think Tank for Osteosarcoma Medical Advisory Board.Sant P Chawla, Brian VAN Tine, Noah Federman, Joseph Schwab, Robin Jones
Anticancer Research. 2024-07-01 - 4 citationsPhase II Trial ofSirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update.Andrew J Wagner, Vinod Ravi, Richard F Riedel, Kristen Ganjoo, Brian A Van Tine
Journal of Clinical Oncology. 2024-05-01 - Editorial: Celebrating the 200th mendel's anniversary: gene-targeted diagnostics and therapies for cancer.Noah Federman, Erlinda M Gordon, Sant P Chawla, Frederick L Hall
Frontiers in Molecular Medicine. 2024-01-01
Press Mentions
- Boy, 11, with Rare Stage 4 Cancer Moves to SoCal to Receive Experimental TreatmentSeptember 30th, 2021
- Family of 11-Year-Old with Cancer Seeks to Raise $500K for Treatment in Santa MonicaSeptember 22nd, 2021
- Deltarex-G Gains Fda Authorization as Adjuvant Therapy for Early-Stage Triple Negative Metaplastic Breast CancerJune 28th, 2021
- Join now to see all
